» Articles » PMID: 23869706

Race, Socioeconomic Status, and Treatment Center Are Associated with Insulin Pump Therapy in Youth in the First Year Following Diagnosis of Type 1 Diabetes

Overview
Date 2013 Jul 23
PMID 23869706
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Increasing numbers of children and adolescents with type 1 diabetes (T1D) have been placed on insulin pump therapy. Nevertheless, data are limited regarding patterns of pump use during the first year of treatment and the clinical and socioeconomic factors associated with early use of pump therapy. Therefore, we sought to determine factors associated with pump therapy within the first year of diagnosis in youth enrolled in the Pediatric Diabetes Consortium (PDC) T1D New-Onset (NeOn) Study.

Subjects And Methods: The NeOn Study includes youth <19 years old at T1D diagnosis who have been followed from the time of diagnosis at seven U.S. pediatric diabetes centers. Cox regression was used to determine factors associated with transition from injection to pump therapy during the first year of T1D in 1,012 participants.

Results: Twenty-seven percent (n=254) of participants began pump therapy within the first year of diagnosis, ranging from 18% to 59% among the seven centers. After adjusting for center effect, factors associated with pump use in multivariate analysis included private health insurance (37% vs. 7%; P<0.001), having annual household income over $100,000 (50% vs. 15%; P<0.001), and non-Hispanic white race (36% vs. 11%; P<0.001). The hemoglobin A1c level did not appear to influence the decision to initiate pump use.

Conclusions: Participants of non-Hispanic white race and higher socioeconomic status were more likely to be placed on pumps during the first year. Further investigations are needed to gain a better understanding of barriers to use of pumps in youth with T1D, especially in disadvantaged and minority families.

Citing Articles

Disparities in Diabetes Technology Uptake in Youth and Young Adults With Type 1 Diabetes: A Global Perspective.

Conway R, Snell-Bergeon J, Honda-Kohmo K, Peddi A, Isa S, Sulong S J Endocr Soc. 2024; 9(1):bvae210.

PMID: 39703363 PMC: 11655873. DOI: 10.1210/jendso/bvae210.


7. Diabetes Technology: Standards of Care in Diabetes-2025.

Diabetes Care. 2024; 48(Supplement_1):S146-S166.

PMID: 39651978 PMC: 11635043. DOI: 10.2337/dc25-S007.


Social and Structural Determinants of Cardiovascular Complications of Diabetes.

Mensah P, Valdez K, Gyawali A, Snell-Bergeon J Curr Diab Rep. 2024; 24(7):147-157.

PMID: 38696042 DOI: 10.1007/s11892-024-01541-7.


Patient Perspectives on the Benefits and Challenges of Diabetes and Digital Technology.

Edelman S, Cheatham W, Norton A, Close K Clin Diabetes. 2024; 42(2):243-256.

PMID: 38666210 PMC: 11040029. DOI: 10.2337/cd23-0003.


Demographic Variables Associated With Diabetes Technology Awareness or Use in Adults With Type 2 Diabetes.

Ye Y, Acevedo Mendez B, Izard S, Myers A Diabetes Spectr. 2024; 37(1):60-64.

PMID: 38385093 PMC: 10877207. DOI: 10.2337/ds23-0013.


References
1.
Willi S, Planton J, Egede L, Schwarz S . Benefits of continuous subcutaneous insulin infusion in children with type 1 diabetes. J Pediatr. 2003; 143(6):796-801. DOI: 10.1067/S0022-3476(03)00579-1. View

2.
Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R . Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care. 1999; 22(5):784-8. DOI: 10.2337/diacare.22.5.784. View

3.
Bode B, Steed R, Davidson P . Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care. 1996; 19(4):324-7. DOI: 10.2337/diacare.19.4.324. View

4.
Shalitin S, Gil M, Nimri R, de Vries L, Gavan M, Phillip M . Predictors of glycaemic control in patients with Type 1 diabetes commencing continuous subcutaneous insulin infusion therapy. Diabet Med. 2010; 27(3):339-47. DOI: 10.1111/j.1464-5491.2009.02925.x. View

5.
Muller-Godeffroy E, Treichel S, Wagner V . Investigation of quality of life and family burden issues during insulin pump therapy in children with Type 1 diabetes mellitus--a large-scale multicentre pilot study. Diabet Med. 2009; 26(5):493-501. DOI: 10.1111/j.1464-5491.2009.02707.x. View